ARB 1467

Drug Profile

ARB 1467

Alternative Names: ARB 1468; ARB-001467; ARB-1467; TKM HBV

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 18 May 2018 Arbutus Biopharma completes a phase II trial in Hepatitis B (Treatment-experienced) in New Zealand, USA, Australia and United Kingdom (IV) (NCT02631096)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Canada (IV, Infusion)
  • 06 Feb 2018 Phase-II clinical trials in Hepatitis B (Combination therapy) in Spain (IV) (EudraCT2017-001647-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top